Herceptin now available for subcutaneous injection

A subcutaneous formulation of the breast cancer treatment Herceptin (trastuzumab) that significantly reduces administration time is now available.

by
HER2 status must be established before starting treatment with Herceptin
HER2 status must be established before starting treatment with Herceptin

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package